title: Sirolimus is highly effective for lymph leakage in microcystic lymphatic malformations with skin involvement.
authors.affiliation: Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
authors.forename: Jochen
authors.identifier: 0000-0003-4022-4917
authors.initials: J
authors.lastname: Rössler
authors.affiliation: Radiology, Children's Hospital Zürich, Zürich, Switzerland.
authors.forename: Julia
authors.initials: J
authors.lastname: Geiger
authors.affiliation: Földiclinic, Hinterzarten, Germany.
authors.forename: Etelka
authors.initials: E
authors.lastname: Földi
authors.affiliation: Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
authors.forename: Denise M
authors.initials: DM
authors.lastname: Adams
authors.affiliation: Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
authors.forename: Charlotte M
authors.initials: CM
authors.lastname: Niemeyer
mesh_terms: D000293:Adolescent; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D044148:Lymphatic Abnormalities / Q000188:drug therapy*; D008297:Male; D020123:Sirolimus / Q000627:therapeutic use*; D012871:Skin Diseases / Q000188:drug therapy*
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus